Login to Your Account

Pancreatic's Days Numbered?

ASCO and Ye Shall Receive: Data Flow Perks Wall Street

By Randy Osborne

Monday, June 7, 2010
The anticipated spill-out of clinical results from the American Society of Clinical Oncology meeting in Chicago continued to, well, spill out as the first part of the week wore on, with outcomes due from various quarters in experiments against a particularly devilish form of cancer: pancreatic. Few tumor types bear a development path as casualty-strewn, other than melanoma - which also promised to yield encouraging news from ASCO. (See BioWorld Insight, May 24, 2010.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription